ArticleJournal of the American College of Cardiology2012
Human cardiac progenitor cells engineered with Pim-I kinase enhance myocardial repair.
Article in Journal of the American College of Cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 156 citations in OpenAlex.
- Pim1 Mitigates Heart Failure by Suppressing Ferroptosis Via Activation of the mTORC1/SLC7A11/GPX4 Axis.Journal of cardiovascular translational research · 2026Article
- Characterization of extracellular vesicles derived from cortical bone stem cells compared with mesenchymal stem cells.Molecular and cellular biochemistry · 2025Article
- Review
- HTK vs. HTK-N for Coronary Endothelial Protection during Hypothermic, Oxygenated Perfusion of Hearts Donated after Circulatory Death.International journal of molecular sciences · 2024Article
- Cardiac Progenitor Cell Metabolism.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Metabolic Changes in Cardiac Aging.Reviews in cardiovascular medicine · 2023Review
- Computational design of custom therapeutic cells to correct failing human cardiomyocytes.Frontiers in systems biology · 2023Article
- Cell-Based and Selected Cell-Free Therapies for Myocardial Infarction: How Do They Compare to the Current Treatment Options?International journal of molecular sciences · 2022Review
- UCP2 modulates cardiomyocyte cell cycle activity, acetyl-CoA, and histone acetylation in response to moderate hypoxia.JCI insight · 2022Article
- Effect of intravenous cell therapy in rats with old myocardial infarction.Molecular and cellular biochemistry · 2022Article
- Comparative proteomic analysis of nuclear and cytoplasmic compartments in human cardiac progenitor cells.Scientific reports · 2022Article
- Cell Surface and Functional Features of Cortical Bone Stem Cells.International journal of molecular sciences · 2021Article
- Transcriptional Profiling of Cardiac Cells Links Age-Dependent Changes in Acetyl-CoA Signaling to Chromatin Modifications.International journal of molecular sciences · 2021Article
- After the storm: an objective appraisal of the efficacy of c-kit+ cardiac progenitor cells in preclinical models of heart disease.Canadian journal of physiology and pharmacology · 2021Review
- Pim1 maintains telomere length in mouse cardiomyocytes by inhibiting TGFβ signalling.Cardiovascular research · 2021Article
- Emerging Roles of Extracellular Vesicles Derived Non-Coding RNAs in the Cardiovascular System.Sub-cellular biochemistry · 2021Article
- Opportunities and Challenges in Stem Cell Aging.Advances in experimental medicine and biology · 2021Review
- Uncoupling protein 2-mediated metabolic adaptations define cardiac cell function in the heart during transition from young to old age.Stem cells translational medicine · 2021Article
- Review
- Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesThe goal of this study was to demonstrate the enhancement of human cardiac progenitor cell (hCPC) reparative and regenerative potential by genetic modification for the treatment of myocardial infarction.
backgroundRegenerative potential of stem cells to repair acute infarction is limited. Improved hCPC survival, proliferation, and differentiation into functional myocardium will increase efficacy and advance translational implementation of cardiac regeneration.
methodshCPCs isolated from the myocardium of heart failure patients undergoing left ventricular assist device implantation were engineered to express green fluorescent protein (hCPCe) or Pim-1-GFP (hCPCeP). Functional tests of hCPC regenerative potential were performed with immunocompromised mice by using intramyocardial adoptive transfer injection after infarction. Myocardial structure and function were monitored by echocardiographic and hemodynamic assessment for 20 weeks after delivery. hCPCe and hCPCeP expressing luciferase were observed by using bioluminescence imaging to noninvasively track persistence.
resultshCPCeP exhibited augmentation of reparative potential relative to hCPCe control cells, as shown by significantly increased proliferation coupled with amelioration of infarction injury and increased hemodynamic performance at 20 weeks post-transplantation. Concurrent with enhanced cardiac structure and function, hCPCeP demonstrated increased cellular engraftment and differentiation with improved vasculature and reduced infarct size. Enhanced persistence of hCPCeP versus hCPCe was revealed by bioluminescence imaging at up to 8 weeks post-delivery.
conclusionsGenetic engineering of hCPCs with Pim-1 enhanced repair of damaged myocardium. Ex vivo gene delivery to modify stem cells has emerged as a viable option addressing current limitations in the field. This study demonstrates that efficacy of hCPCs from the failing myocardium can be safely and significantly enhanced through expression of Pim-1 kinase, setting the stage for use of engineered cells in pre-clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.